Recombinant human interleukin-6 enhances the antiproliferation and differentiation inducing effects of retinoic acid in HL-60 human myeloid leukaemic cells.
1. The effect of recombinant human interleukin-6 on the antiproliferation and differentiation inducing actions of all-trans retinoic acid in HL-60 human myeloid leukaemia cells was studied in short-term liquid suspension culture. 2. Interleukin-6 alone showed no significant effect on HL-60 human myeloid leukaemia cells. 3. The addition of interleukin-6 to all-trans retinoic acid-treated cultures of HL-60 human myeloid leukaemia cells significantly enhanced the desired antiproliferation effect of all-trans retinoic acid. 4. The combination of interleukin-6 with all-trans retinoic acid reduced the doses of all-trans retinoic acid required to induce the same differentiation of HL-60 cells as single agent by between 1.7- and 4.8-fold; that is, the efficacy of all-trans retinoic acid in inducing the differentiation of human myeloid leukaemia HL-60 cells was increased up to 4.8 times by its combination with interleukin-6. 5. The combination of all-trans retinoic acid and interleukin-6 could provide an effective alternative therapy for elderly myeloid leukaemia patients.
Hassan
H T
HT
Institut für Pharmazie, Freie Universität Berlin, Germany.
D002454:Cell Differentiation / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects*; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology*; D007951:Leukemia, Myeloid / Q000473:pathology; D011994:Recombinant Proteins / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000473:pathology
D015850:Interleukin-6; D011994:Recombinant Proteins; D014212:Tretinoin